*Reference Range Female/Male (μg/mg Cr) | Total (N=17) | tAMD (N=8) | PCV (N=9) | P Value tAMD vs PCV | |
---|---|---|---|---|---|
Pyruvate | |||||
Concentration (μg/mg Cr) | 0.6-6.6/0.5-5.9 | 8.0 ± 2.8 | 8.3 ± 3.1 | 7.7 ± 2.4 | **0.3502 |
% Increase | - | 83.6 ± 51.1 | 93.4 ± 59.0 | 74.9 ± 41.0 | **0.2500 |
Abnormal level | - | 11/17 (64.7%) | 5/8 (62.5%) | 6/9 (66.6%) | †0.6267 |
Lactate | |||||
Concentration (μg/mg Cr) | 0.0-1.6/0.0-1.6 | 7.5 ± 8.3 | 4.6 ± 5.4 | 10.1 ± 9.6 | **0.0960 |
% Increase | - | 426.5 ± 527.8 | 244.2 ± 343.4 | 588.5 ± 604.7 | **0.0960 |
Abnormal level | - | 12/17 (70.6%) | 5/8 (62.5%) | 7/9 (77.7%) | †0.4367 |
α-Hydroxybutyrate | |||||
Concentration (μg/mg Cr) | 0.2-2.8/0.2-2.8 | 0.6 ± 0.4 | 0.5 ± 0.4 | 0.7 ± 0.4 | **0.1233 |
% Increase | - | -31.9 ± 15.2 | -36.7 ± 15.6 | -27.6 ± 13.5 | **0.1233 |
Abnormal level | - | 0/17 (0.0%) | 0/8 (0.0%) | 0/9 (0.0%) | †NA |
β-Hydroxybutyrate | |||||
Concentration (μg/mg Cr) | 0.0-1.9/0.0-1.9 | 0.3 ± 0.3 | 0.3 ± 0.3 | 0.4 ± 0.3 | **0.3406 |
% Increase | - | -33.1 ± 17.5 | -35.1 ± 17.6 | -31.3 ± 17.2 | **0.3406 |
Abnormal level | - | 0/17 (0.0%) | 0/8 (0.0%) | 0/9 (0.0%) | †NA |
Lactate/Pyruvate ratio | |||||
Value | 0.1-0.2/0.1-0.2 | 0.9 ± 0.9 | 0.6 ± 0.7 | 1.2 ± 1.0 | **0.0955 |
% Increase | - | 315.0 ± 369.9 | 250.8 ± 173.6 | 440.7 ± 411.1 | **0.0734 |
Abnormal value | - | 12/17 (70.6%) | 5/8 (62.5%) | 7/9 (77.7%) | †0.4367 |